August 12, 2016 5:20pm
… Identifies risk capacity versus risk tolerance as a daily concept
Enhancing trading influences with a willingness to stomach the swings and uncertainty
… And preps next week’s shakeout moves
Pre-open indication’s tally: 3 hits and 4 miss:
I answer one question; in which company should investors put, keep and commit their money!
Do you care what happened today, you should … because it has implications to Monday's sector activity? Where has today’s market gone – subscribe and find out.
There are two things that investors need - interpretation of news and translation of market metrics concerning the stem, cell, gene and regenerative therapy sector to substantiate share pricing.
U.S. equities closed mostly lower on Friday as investors digested disappointing economic data, following a record-setting day on Thursday.
The NASDAQ closed UP +4.50 or +0.09% to 5,232.90 and the DOW closed DOWN -37.05 or -0.20% to 18,576.47.
A day in the life of the stem, cell, gene and regenerative therapy (SCGT & RT) sector – the advance/decline line scenario of our 43 covered companies:
- The open was negative with an A/DL of 18/22 and 3 flats;
- The mid-day turned positive with an A/DL of 26/15 and 2 flats;
- The closing bell was positive with A/DL of 27/14 and 2 flats;
Henry’omics:
The stem, cell, gene and regenerative therapies sector defies the predictions of many but, lately I have been on the mark i.e. the tip of the spear.
- Volume, the mother's milk of any intermediate-term rally, is slightly better on the NASDAQ than during Q2’s peripatetic movements.
“Our” universe has also been experiencing the effects of the summer season’s slow period due to the many vacationing participants.
The stem, cell, gene and regenerative therapy (SCGT&RT) sector opened negative, flipped positive before the mid-day with the sector closing positive.
- The iShares Nasdaq Biotechnology NASDAQ GM (IBB) was UP +0.21%
- The iShares Russell 2000 NYSE Arca (IWM) was UP +0.10%,
- The SPDR S&P Biotech ETF (XBI) was UP +0.92% and
- The Health Care Select Sector SPDR ETF (XLV) was DOWN -0.19%.
The CBOE Volatility index (VIX), widely considered the best gauge of fear in the market, traded about 1.4% lower, near 11.5.
Call me cantankerous, contrarian or even a curmudgeon but at the least I get it right …
Pre-open indication’s tally: 3 hits and 4 miss:
- AxoGen (AXGN) closed UP +$0.12 – miss;
- BioLife Solutions (BLFS) closed UP +$0.05 – miss;
- Biostage (BSTG) closed DOWN -$0.03 – hit;
- bluebird bio (BLUE) closed UP +$1.32 – miss;
- Caladrius Biosciences (CLBS) closed DOWN -$0.06 – hit;
- Mesoblast (MESO) closed UP +$0.80 – miss;
- Spark Therapeutics (ONCE) closed DOWN -$1.17 – hit;
Review my fear gauge or the CBOE Volatility Index (VIX):
- Friday traded near 11.5;
- Thursday traded near 11.6;
- Wednesday traded near 12.5;
- Tuesday traded near 1.6;
- Monday traded near 11.5;
- Last Friday traded near 11.3;
Today’s Bottom Line:
Always thank you for an up day and then worried about the effect on the next Monday's session …
Decliners:
- Neuralstem (CUR) -9.28%;
- Northwest Bio (NWBO)-4.36%;
- Biostage (BSTG) -2.63%;
- Fibrocell (FCSC) -2.70%;
- Spark Therapeutics (ONCE) -1.85%
Advancers:
- Regenxbio (RGNX) +15.35% after Thursday’s +4.29% post Wednesday’s -8.43% after Tuesday’s +10.35% post Monday’s +9.09%
- Mesoblast (MESO) +14.04% after Thursday’s +15.53%;
- Cytori (CYTX) +9.04%;
- Fate Therapeutics (FATE) +7.56%;
- Histogenics (HSGX) +6.05%
Flat:
- Opexa (OPXA) at $4.19;
- ReNeuron (RENE.L) at $2.875;
Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.
Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.
